Anti-Canine CD44 FITC 100 tests
- Known as:
- Antibody toCanine CD44 fluorecein 100 tests
- Catalog number:
- 11-5440-42
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Canine CD44 FITC 100 tests
Related genes to: Anti-Canine CD44 FITC 100 tests
- Gene:
- CD44 NIH gene
- Name:
- CD44 molecule (Indian blood group)
- Previous symbol:
- MIC4, MDU2, MDU3
- Synonyms:
- IN, MC56, Pgp1, CD44R, HCELL, CSPG8
- Chromosome:
- 11p13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2019-04-23
Related products to: Anti-Canine CD44 FITC 100 tests
Alkaline Phosphatase Conjugated Affinity Purified anti-Swine IgG (H&L) [Goat] Secondary_Antibodies#10 Rubber Bands, 1Lb Box Pale Crepe Gold#10 Rubber Bands, 1Lb Box Pale Crepe Gold#10 Rubber Bands, 1Lb Box Pale Crepe Gold(-)-Epigallocatechin gallate(-)-Epigallocatechin gallate (EGCG)(-)-JQ1(-)-Scopolamine Perchlorate (Hyoscine perchlorate)(d,l)-Tetrahydroberberine (Canadine)(d,l)_Tetrahydroberberine (Canadine)(Deamino_Phe19,D_Ala24,D_Pro26_(®)_Phe27)_GRP (19_27) (human, porcine, canine) Salt Trifluoroacetate Binding _ Synonym BW_10 SumFormula C57H72N14O8(Deamino_Phe19,D_Ala24,D_Pro26_(®)_Phe27)_GRP (19_27) (human, porcine, canine) Salt Trifluoroacetate Binding _ Synonym BW_10 SumFormula C57H72N14O8(Draxin) C1ORf187 FITC-conjugates: Drax-FITC Host: Rabbit Affinity purifed Related articles to: Anti-Canine CD44 FITC 100 tests
- The malignant progression of renal cell carcinoma (RCC) is closely associated with the establishment of an immunosuppressive tumor microenvironment (TME). This study aims to elucidate the oncogenic functions of DNA polymerase ε subunit POLE2 in RCC and its mechanism in modulating the tumor immune microenvironment. We found that POLE2 was significantly upregulated in clear cell RCC (ccRCC) tissues and cell lines. Gain-of-function and loss-of-function experiments demonstrated that POLE2 markedly enhanced tumor cell proliferation, migration, and tumorigenicity both in vitro and in vivo. Mechanistically, POLE2 binds to the PCNA-associated factor PCLAF and stabilizes the PCLAF protein by inhibiting its ubiquitin-proteasome-mediated degradation, thereby leading to increased expression and secretion of SPP1/osteopontin (OPN) in tumor cells. OPN acts as a key cytokine that drives macrophage M2 polarization by activating the CD44/integrin receptors on macrophages and their downstream STAT6 signaling pathway. Moreover, we identified the transcription factor NFATc2 as an upstream regulator of POLE2, which directly binds to the POLE2 promoter and activates its transcription. Our study unveils a comprehensive NFATc2/POLE2/PCLAF signaling axis that promotes ccRCC progression via OPN-mediated M2 macrophage polarization, providing a solid rationale and potential therapeutic targets for developing novel immunocombination therapies. - Source: PubMed
Publication date: 2026/09/22
Li An-RuiXu Jing-WenWu Zhi-HangKang Zhi-JianLuo Run-ShengSu Ya-JuanYuan QiTeng Li-Chen - Curcumin and bone marrow-derived mesenchymal stem cells (BMSCs) with osteogenic differentiation potential can promote tendon-bone healing. This study revealed the specific mechanisms by which curcumin promotes osteogenic differentiation of BMSCs. - Source: PubMed
Zeng ZhaoyongBao ZhiqiangZhang JianpingChen XianyiFu XuanjianChen YangCai Daozhang - Previously OTP, CD44 and Ki-67 have been identified as prognostic biomarkers in lung carcinoids (lung neuroendocrine tumors or LNETs). We aimed to assess whether risk profiles can be established using these biomarkers on preoperative LNET biopsies . Patients with LNETs (TNM 8 stage I-III, 2003-2021) who underwent curative resection were selected from Dutch pathology registry (PALGA). Immunohistochemistry for OTP, CD44 and Ki-67 (biomarkers) was performed on matched resection and biopsy (Bx) specimens. Three pathologists revised all cases per the WHO 2021 classification (WHO). OTP and CD44 were assessed by H-score, Ki-67 proliferation index (PI) by eyeball hot-spot scoring. Bx cases diagnosed as carcinoid not otherwise specified (NOS) were considered low risk for relapse and atypical carcinoid (AC) as high risk. Immunostained cases were classified as low risk (OTP≥50, CD44≥30, Ki-67<5%) or high risk (others). Ninety-eight patients were eligible. Nineteen relapse events occurred after a median follow-up of 83 months. The biomarkers correctly identified high risk in 89% (n=17/19) of relapses, outperforming the WHO classification, which assigned 11% (n=2/19) of relapses as AC. Negative predictive value of biomarkers was 0.96 compared to 0.82 for WHO. The biomarkers showed greater prognostic stratification in relapse-free survival analysis and higher inter-observer agreement (biomarkers: κ=0.673; WHO: κ=0.276, both p<0.001). Biomarker expression was more stable between biopsy and resection specimen, improving concordance compared to WHO (biomarkers: κ=0.584, p<0.001; WHO: κ=0.169, p=0.037). In conclusion, an OTP, CD44, and Ki-67 biomarker panel enables reliable identification of low risk LNETs on Bx, outperforming WHO classification for prognostic stratification and biopsy-resection concordance. By accurately identifying tumors with a molecular low risk profile on preoperative biopsies, this panel may help to guide treatment choice for patients considered for sublobar resection. - Source: PubMed
Publication date: 2026/09/21
van Weert Tijmen J JMoonen LauraHillen Lisa Mvon der Thüsen Jan Hden Bakker Michael ALap Lisa M VMarshall Ambar C Evan den Broek EstherDamhuis Ronald ABuikhuisen Wieneke ADingemans Anne-Marie CDerks Jules LSpeel Ernst Jan M - Tumor-targeted and stimuli-responsive nanocarriers have emerged as promising platforms for improving the efficacy and safety of chemotherapy. Herein, we developed a polyethylene glycol- hyaluronic acid-epigallocatechin-3-O-gallate (PEG-HA-EGCG) nanoplatform that integrates polyphenol-mediated drug loading, CD44-targeted delivery, and tumor-responsive doxorubicin (DOX) release. The amphiphilic PEG-HA-EGCG conjugate spontaneously self-assembled into stable micellar nanoparticles comprising a hydrophobic EGCG-rich core and a hydrophilic HA-PEG shell. The abundant aromatic rings and hydroxyl groups of EGCG promoted strong π-π stacking and hydrogen-bonding interactions with DOX, resulting in a high drug-loading efficiency of up to 93% while maintaining nanoparticle stability. Notably, the micelles remained relatively stable under physiological conditions while exhibiting triple-responsive DOX release triggered by acidic pH, reductive conditions, and elevated HAase levels in the tumor microenvironment. The HA shell facilitated CD44 receptor-mediated cellular uptake and enhanced antitumor effects in the 3D spheroid model. Consequently, PEG-HA-EGCG@DOX demonstrated intracellular DOX accumulation and anticancer activity in vitro and achieved tumor growth suppression comparable to free DOX, with reduced systemic toxicity in vivo. These findings demonstrate the potential of PEG-HA-EGCG micelles as a polysaccharide-based nanoplatform integrating high-capacity drug loading, tumor-responsive release, and targeted intracellular delivery for cancer therapy. - Source: PubMed
Publication date: 2026/09/21
Nguyen Dinh TrungNguyen Hoang DuyHoang Anh QuanThi Ngoc Dung DuongTu Quang AnhTruong Minh-DungSai Duc LocPham Dinh-ChuongLe Thi Phuong - Pheochromocytomas (PCCs) in dogs are challenging to diagnose. Plasma proteomics offers a minimally invasive approach to identify circulating biomarkers and disease-relevant pathways. - Source: PubMed
van den Berg Marit FRodríguez-Rojas AlexandroDoulidis Pavlos GPisoni LucianoBurgener Iwan AGalac Sara